Real world management of multiple myeloma patients
Real world management of multiple myeloma patients
Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5-year results
Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM patients
FORTE trial: Impact of minimal residual disease on multiple myeloma patients
Evaluation of MRD negativity in patients with relapsed or refractory multiple myeloma treated in the CANDOR study
Neurocognitive impairment in long-term survivors of childhood Hodgkin lymphoma
Hyper-CVAD and sequential blinatumomab in adults with newly diagnosed Philadelphia chromosome-negative B-cell ALL
Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory Philadelphia chromosome-positive ALL
Clinical implications of MRD detection in infants with KMT2A-rearranged ALL Treated on the Interfant-06 protocol
Predictive factors for overall survival in chronic myeloid leukaemia patients: an analysis by the Gimema CML Italian study
Cranial radiation mostly eliminated in children with T-ALL and bortezomib potentially improves survival in children with T-LL
Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukaemia